Pharmaceuticals, Biotechnology and Life Sciences
Kodiak Sciences will present emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) in San Francisco, in an upcoming event, at the Annual Meeting of the American Academy of Ophthalmology (AAO).
Nevakar, ophthalmology specialist pharmaceutical company has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
MJH Life Sciences said Wednesday it has promoted Mike Hennessy Jr. to dual role of president/CEO, effective today.
Author John Hawkins has written a well-researched biography about Termeer’s legacy—how he built a global biotech giant, Genzyme, and mentored…
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter from SWK related to certain financial covenants for Q3 2019.
MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured,…
Catabasis Pharmaceuticals has enrolled more than expected patients for its third phase PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD), for which it expects the top-line results in the fourth quarter of 2020.
Arrowhead Pharmaceuticals have announced participating in several conferences in October, covering cystic fibrosis, Oligonucleotide-Based Therapeutics, and genetic medicines topics.
FDA has approved Invokana (canagliflozin) to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD, which is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.